CML patients with stable response may safely decrease dose of TKI
3 Dec 2016
CML patients with stable response may safely decrease dose of TKI
International Aspirin Foundation Senior Science Award winner
Cancer care in Kazakhstan
Advanced oral cancer in St Petersburg
Editor's Choice for November 2016
Research engagement among black men with prostate cancer
Gold nanoparticles and cancer treatment
BMI trajectories: Obesity related cancer risk
Palliative and end of life care
Minimum unit pricing for alcohol: The most cost-effective cancer prevention strategy of all?
Managing breast cancer in low and middle income countries
Non surgical treatment of rectal cancer